Santen Pharmaceutical Statistics
Share Statistics
Santen Pharmaceutical has 342.44M
shares outstanding. The number of shares has increased by -11.09%
in one year.
| Shares Outstanding | 342.44M |
| Shares Change (YoY) | -11.09% |
| Shares Change (QoQ) | -4.1% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,462 |
| FTD / Avg. Volume | 64.43% |
Short Selling Information
The latest short interest is 59, so 0% of the outstanding
shares have been sold short.
| Short Interest | 59 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 19.57 and the forward
PE ratio is null.
Santen Pharmaceutical's PEG ratio is
-0.07.
| PE Ratio | 19.57 |
| Forward PE | n/a |
| PS Ratio | 1.73 |
| Forward PS | 0 |
| PB Ratio | 1.7 |
| P/FCF Ratio | 8.41 |
| PEG Ratio | -0.07 |
Financial Ratio HistoryEnterprise Valuation
Santen Pharmaceutical has an Enterprise Value (EV) of 461.88B.
| EV / Sales | 1.53 |
| EV / EBITDA | 9.11 |
| EV / EBIT | 6.36 |
| EV / FCF | 7.45 |
Financial Position
The company has a current ratio of 2.54,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.54 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 0.57 |
| Interest Coverage | 14.47 |
Financial Efficiency
Return on Equity is 8.7% and Return on Invested Capital is 10.05%.
| Return on Equity | 8.7% |
| Return on Assets | 6.11% |
| Return on Invested Capital | 10.05% |
| Revenue Per Employee | $80,653,044.87 |
| Profits Per Employee | $7,115,918.8 |
| Employee Count | 3,744 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.85 |
Taxes
| Income Tax | 3.17B |
| Effective Tax Rate | 10.61% |
Stock Price Statistics
The stock price has increased by 13.07% in the
last 52 weeks. The beta is 0.2, so Santen Pharmaceutical's
price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | 13.07% |
| 50-Day Moving Average | 9.9 |
| 200-Day Moving Average | 10.73 |
| Relative Strength Index (RSI) | 66.48 |
| Average Volume (20 Days) | 5,373 |
Income Statement
In the last 12 months, Santen Pharmaceutical had revenue of 301.96B
and earned 26.64B
in profits. Earnings per share was 72.62.
| Revenue | 301.96B |
| Gross Profit | 178.71B |
| Operating Income | 38.54B |
| Net Income | 26.64B |
| EBITDA | 50.72B |
| EBIT | 32.54B |
| Earnings Per Share (EPS) | 72.62 |
Full Income StatementBalance Sheet
The company has 94.58B in cash and 35.16B in
debt, giving a net cash position of 59.42B.
| Cash & Cash Equivalents | 94.58B |
| Total Debt | 35.16B |
| Net Cash | 59.42B |
| Retained Earnings | 240.03B |
| Total Assets | 434.16B |
| Working Capital | 143.97B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 72.65B
and capital expenditures -10.69B, giving a free cash flow of 61.96B.
| Operating Cash Flow | 72.65B |
| Capital Expenditures | -10.69B |
| Free Cash Flow | 61.96B |
| FCF Per Share | 168.88 |
Full Cash Flow StatementMargins
Gross margin is 59.18%, with operating and profit margins of 12.76% and 8.82%.
| Gross Margin | 59.18% |
| Operating Margin | 12.76% |
| Pretax Margin | 9.89% |
| Profit Margin | 8.82% |
| EBITDA Margin | 16.8% |
| EBIT Margin | 12.76% |
| FCF Margin | 20.52% |
